SCHEMBL4886602

SCHEMBL4886602

BrC1C2CC3CC(C2)CC1(I)C3

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A2 O15244 2/20 0.32
SLC47A1 Q96FL8 2/20 0.32
LMNA P02545 2/20 0.32
SLC22A1 O15245 1/20 0.32
GRIN2D O15399 1/20 0.32
GRIN3B O60391 1/20 0.32
TSHR P16473 1/20 0.32
NFKB1 P19838 1/20 0.32
STAT6 P42226 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2A Q12879 1/20 0.32
GRIN2B Q13224 1/20 0.32
GRIN2C Q14957 1/20 0.32
GRIN3A Q8TCU5 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
POLB P06746 1/20 0.31
THRB P10828 1/20 0.31
BLM P54132 1/20 0.31
PMP22 Q01453 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4055795 0.74 GRIN2D (0.35) SLC22A2SLC47A1LMNASLC22A1GRIN2D
SCHEMBL2745866 0.72 SLC22A2 (0.33) SLC22A2SLC47A1LMNASLC22A1GRIN2D
SCHEMBL4992238 0.70 GRIN2D (0.30) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL28215771 0.69 THRB (0.35) THRB
SCHEMBL4059493 0.68 SLC22A2 (0.31) SLC22A2SLC47A1LMNASLC22A1GRIN2D
SCHEMBL4439385 0.65 GRIN2D (0.39) SLC22A2SLC47A1LMNASLC22A1GRIN2D
SCHEMBL5498257 0.65
SCHEMBL8796698 0.64
SCHEMBL761698 0.62 GRIN2D (0.44) SLC22A2SLC47A1LMNASLC22A1GRIN2D
SCHEMBL4054861 0.62 LMNA (0.33) SLC22A2SLC47A1LMNASLC22A1GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275112-A1 Invention Concerning Aminoadamantane Compounds SCHREINER PETER R 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275112-A1 Invention Concerning Aminoadamantane Compounds GABRA5, GABRA1, GABRA4 SLC22A2 3057/4885SLC47A1 593/4885LMNA 3362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.